AJR F and L Medical Products: Radiation Protection & More
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, B. D.
Right arrow Articles by Goellner, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, B. D.
Right arrow Articles by Goellner, J. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
AJR 2002; 178:699-704
© American Roentgen Ray Society


Percutaneous Ethanol Injection for Treatment of Cervical Lymph Node Metastases in Patients with Papillary Thyroid Carcinoma

B. D. Lewis1, I. D. Hay2, J. W. Charboneau1, B. McIver2, C. C. Reading1 and J. R. Goellner3

1 Department of Radiology, Mayo Clinic and Mayo Foundation, 200 First St., SW, Rochester, MN 55905.
2 Division of Endocrinology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905.
3 Department of Surgical Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905.

OBJECTIVE. The objective of this study was to evaluate the technique, efficacy, and side effects of percutaneous ethanol injection in patients with limited cervical nodal metastases from papillary thyroid carcinoma.

SUBJECTS AND METHODS. Fourteen patients who had undergone thyroidectomy for papillary thyroid carcinoma presented with limited nodal metastases (one to five involved nodes) in the neck between May 1993 and April 2000. All patients had received previous iodine-131 ablative therapy with a mean total dose per patient of 7,548 MBq. Ten of the patients either were considered poor surgical candidates or preferred not to have surgery, and all were unresponsive to iodine-131 therapy. Each metastatic lymph node was treated with percutaneous ethanol injection, and patients received both clinical and sonographic follow-up.

RESULTS. Twenty-nine metastatic lymph nodes in our 14 patients were injected. Mean sonographic follow-up was 18 months (range, from 2 months to 6 years 5 months). All treated lymph nodes decreased in volume from a mean of 492 mm3 before percutaneous ethanol injection to a mean volume of 76 mm3 at 1 year and 20 mm3 at 2 years after treatment. Six nodes were re-treated 2-12 months after initial percutaneous ethanol injection because of persistent flow on color Doppler sonography (n = 4), stable size (n = 1), or increased size (n = 1). Two patients developed four new metastatic nodes during the follow-up period that were amenable to percutaneous ethanol injection. Two patients developed innumerable metastatic nodes that precluded retreatment with percutaneous ethanol injection. No major complications occurred. All patients experienced long-term local control of metastatic lymph nodes treated by percutaneous ethanol injection. In 12 of 14 patients, percutaneous ethanol injection was successful in controlling all known metastatic adenopathy.

CONCLUSION. Sonographically guided percutaneous ethanol injection is a valuable treatment option for patients with limited cervical nodal metastases from papillary thyroid cancer who are not amenable to further surgical or radioiodine therapy.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Br. J. Radiol.Home page
M YING and B S F PANG
Three-dimensional ultrasound measurement of cervical lymph node volume
Br. J. Radiol., August 1, 2009; 82(980): 617 - 625.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
N. A. Johnson and M. E. Tublin
Postoperative Surveillance of Differentiated Thyroid Carcinoma: Rationale, Techniques, and Controversies
Radiology, November 1, 2008; 249(2): 429 - 444.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. T. Kloos
Approach to the Patient with a Positive Serum Thyroglobulin and a Negative Radioiodine Scan after Initial Therapy for Differentiated Thyroid Cancer
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1519 - 1525.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Triponez, L. Poder, R. Zarnegar, R. Goldstein, K. Roayaie, V. Feldstein, J. Lee, E. Kebebew, Q.-Y. Duh, and O. H. Clark
Hook Needle-Guided Excision of Recurrent Differentiated Thyroid Cancer in Previously Operated Neck Compartments: A Safe Technique for Small, Nonpalpable Recurrent Disease
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4943 - 4947.
[Abstract] [Full Text] [PDF]


Home page
J Ultrasound MedHome page
AIUM Practice Guideline for the Performance of a Thyroid and Parathyroid Ultrasound Examination
J. Ultrasound Med., October 1, 2003; 22(10): 1126 - 1130.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Roentgen Ray Society.